Tissue distribution and clearance of intravenously administered titanium dioxide (TiO2) nanoparticles
Tissue distribution and clearance of intravenously administered titanium dioxide (TiO2) nanoparticles
复制标题
DOI：
10.3109/17435390.2012.763001
复制
发表时间：
2014-03-01
期刊：
影响因子：
5
通讯作者：
Gamo, Masashi
中科院分区：
文献类型：
--
作者：
Shinohara, Naohide;Danno, Nobuko;Gamo, Masashi
使用电感耦合等离子体扇形场质谱仪测定大鼠静脉给药（0.95 mg/kg体重）后Degussa P25 TiO 2纳米颗粒的器官-组织分布和清除率。Ti分析的检测限（血液和尿液的检测限为0.54和1.4 ng/mL，几种器官组织的检测限为0.35-2.0 ng/g组织）使得能够测定先前由于低浓度而无法测定Ti含量的器官的组织分布和清除率。给药后5分钟和15分钟，TiO 2的血液浓度分别为420和19 ng/mL，分别仅相当于给药剂量的2.8%和0.13%。在6 h时，在肝、脾、肺、肾、心脏和血液中分别发现94%、2.0%、0.17%、0.023%、0.014%和0.026%的给药TiO 2。给药组的肝脏和脾脏TiO 2负荷显著高于对照组（p < 0.01），并且在给药后30天内未降低，而肺、肾、心脏和血液中的TiO 2负荷随时间推移而降低。两步衰减模型比一步衰减模型更适合于肺TiO 2负荷的衰减曲线，但并未改善与肾TiO 2负荷衰减曲线的拟合。在比先前研究中应用的检测限更低的检测限下，证实没有易位到大脑。TiO 2给药组粪便和尿液中的Ti含量与对照组无差异。
The organ-tissue distribution and clearance of Degussa P25 TiO2 nanoparticles were determined after intravenous administration to rats (0.95 mg/kg body weight) using an inductively coupled plasma sector field mass spectrometer. The detection limits of Ti analysis, 0.54 and 1.4 ng/mL for blood and urine and 0.35-2.0 ng/g tissue for several organ tissues, enabled determination of tissue distribution and clearance for organs in which Ti content could not be previously determined due to low concentrations. Blood concentrations of TiO2 were 420 and 19 ng/mL at 5 and 15 min after administration, which were equivalent of only 2.8% and 0.13% of the administration dose, respectively. At 6 h, 94%, 2.0%, 0.17%, 0.023%, 0.014% and 0.026% of administered TiO2 was found in the liver, spleen, lung, kidney, heart and blood, respectively. Liver and spleen TiO2 burden was significantly higher in the administration than control group (p < 0.01) and did not decrease up to 30 days after administration, while TiO2 burden in the lung, kidney, heart and blood decreased over time. A two-step decay model was more suitable than a one-step decay model for the decay curves of pulmonary TiO2 burden but did not improve fitting to the decay curves of kidney TiO2 burden. No translocation to the brain was confirmed at a lower detection limit than was applied in previous studies. Ti content in faeces and urine in the TiO2 administration group did not differ from that in the control group.